NGS Testing Challenges and Considerations in NSCLC

One patient with metastatic bladder cancer experienced an ongoing metabolic complete response following treatment with aldesleukin/imneskibart.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Dato-DXd is being assessed in numerous trials across the breast, lung, and bladder cancer spaces.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Data from the phase 2 TUXEDO-3 trial support patritumab deruxtecan as a novel treatment option across different cancer populations with brain metastases.

Data from the REZILIENT2 trial show meaningful intracranial activity in patients with NSCLC harboring EGFR exon 20 insertions or other uncommon mutations.